- Tags: retina
Pipeline
FDA grants RMAT designation to 4DMT for DME gene therapy
4D-150 provides a multi-year sustained delivery of anti-VEGF from the retina via a single, low-dose IVT delivery—potentially reducing the need for frequent bolus injections.
Products
OcuSciences receives FDA clearance for retinal health assessment tool
The OcuMet Beacon, a confocal scanning ophthalmoscope, is indicated to provide a rapid, pain-free, and noninvasive imaging evaluation for earlier disease detection.
Research
New technology targets photoreceptor cells to create a novel color
Oz prototype system allows for perception of “olo,” a blue-green color not visible in natural vision.
Research
Smoking among factors linked to retinal vessel trait changes
Association with larger retinal arteriolar and venular size may have important implications for ocular health.
Business
Topcon names former Genentech exec as chief medical officer
Daniela Ferrara, MD, PhD’s role involves establishing retinal imaging as a first-line tool for both eyecare and the screening and management of complex systemic diseases.
Research
Study connects HDL levels to AMD development
Key finding: A U-shaped relationship between low and high HDL and increased risk of AMD.
Research
Safety and efficacy data supports Vista 1-Step vitrectomy probe
A total of 86% of pseudophakic patients reported a complete resolution of symptoms by postop month 3 following limited vitreous removal procedure.
Business
BVI Medical and Neurotech name new CCOs
With over 20 years of executive leadership experience each, Andrew Chang and Beth Marsh will lead commercialization efforts for their respective companies’ upcoming product launches.
Business
Voiant acquires AI-based ophthalmic image analysis startup Voxeleron
Software and clinical trial expertise to combine into an AI-based integrated platform for retinal and corneal imaging, with a goal of expedited patient treatment delivery.
Products
FDA accepts Regeneron's EYLEA HD sBLA for priority review
Agency sets target action date of Aug. 19 to consider a new indication for macular edema following RVO and expanded monthly dosing.
Pipeline
Phase 3 enrollment concludes for Oculis' DME eye drop program
Topline data readout expected Q2 2026 as lead candidate OCS-01 has the potential to become the first noninvasive eye drop indicated to treat this retinal disease.
Products
Settlement paves way for US commercialization of Eylea biosimilar
Biocon Biologic’s YESAFILI (aflibercept-jbvf) now expected to launch in H2 2026 after dismissal of Regeneron’s patent infringement lawsuits.
Research
Are uveitis patients at an increased risk for complications post-cataract surgery?
Postoperative complications varied based on the uveitis subtype.
Pipeline
FDA grants RMAT designation to Atsena's XLRS gene therapy
This marks ATSN-201’s fourth designation in the FDA’s expedited drug development program, propelling it one step closer to becoming the first approved treatment for this IRD.
Research
Do you need to treat subretinal fluid in AMD?
Review outlines a proposed algorithm for evaluating subretinal fluid in nAMD patients.
Pipeline
Pykus concludes study enrollment for post-RD surgery retinal sealant
Biodegradable, focal hydrogel retinal sealant could replace the need for medical gases or silicone oil, eliminate face-down positioning, and accelerate visual recovery.
Pipeline
Opus Genetics reports first-in-human trial data on LCA gene therapy
One-month findings from the first of three pediatric dosings indicate a clinically meaningful improvement in vision following just one dosing.
Pipeline
FDA accepts Outlook Therapeutics' bevacizumab BLA for wet AMD
With a PDUFA date of Aug. 27, ONS-5010 (LYTENAVA) could become the first FDA-approved bevacizumab formulation targeting this retinal disease.
Research
Hormones may play key role in DR risk among diabetes patients
Surprising findings reveal how sex hormones may secretly influence the risk for diabetic retinopathy.
Research